Real-world Evidence of Inebilizumab in IgG4-RD (REDUCE)
Real-world Evidence of Inebilizumab in Decreasing Corticosteroid Use and Improving Clinical Efficacy in IgG4-RD
The goal of this observational study is to observe the efficacy and safety of inebilizumab in the treatment of IgG4-related disease. The main question it aims to answer the optimal steroid-sparing regimen for patients with IgG4-RD in clinical practice.
This study will enroll all patients with IgG4-RD treated with inebilizumab. Enrolled patients will receive different treatment regimens according to disease severity and whether they are taking other immunosuppressive agents.
Przegląd badań
Status
Status
Warunki
Warunki
Szczegółowy opis
All enrolled patients will be categorized into four subtypes based on disease severity and concomitant use of other immunosuppressive agents:
Group1 Treatment-naive active disease treated with inebilizumab monotherapy group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that the disease is suitable for inebilizumab monotherapy; Group2 Treatment-naive active disease treated with short-course corticosteroids plus inebilizumab group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that short-course corticosteroids are required in combination; Group3 Stable disease continued-treatment group: patients with stable disease control on long-term corticosteroids or corticosteroids plus conventional immunosuppressants, who are at high risk of relapse after discontinuation and are willing to switch to a steroid-free inebilizumab treatment regimen; Group4 Relapsed/refractory patient group: patients who experience relapse while receiving corticosteroids or corticosteroids combined with immunosuppressants.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Linyi Peng
- Numer telefonu: +86-10-69155004
- E-mail: drpenglinyi@163.com
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
All IgG4-related disease patients treated with inebilizumab.
Opis
Inclusion Criteria:
- Aged ≥18 years old;
- Meet the 2019 ACR/EULAR classification criteria or the 2020 Japanese diagnostic criteria for IgG4-RD;
- Plan to receive treatment with inebilizumab;
- Signed informed consent form.
Exclusion Criteria:
- Pregnant or lactating female patients;
- Participation in other interventional studies within 30 days prior to screening, or exposure to investigational products within 5 half-lives before enrollment, or planned participation in other interventional studies during the trial period;
- Patients with contraindications to inebilizumab treatment;
- Any other conditions deemed inappropriate for enrollment by the investigator.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: CROSS_SECTIONAL
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
|---|
|
Patients with IgG4-RD treated with inebilizumab
Patients with IgG4-RD receiving inebilizumab in the real-world setting |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Relapse rate
Ramy czasowe: One year after inebilizumab treatment
|
Flare of IgG4-RD is defined as the reappearance of previous symptoms or signs of IgG4-RD or the appearance of new symptoms or signs attributed to IgG4-RD, based on clinical assessment, laboratory tests, and/or imaging, and reflected by an increase in the IgG4-RD Responder Index |
One year after inebilizumab treatment
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proportion of subjects achieving flare-free and treatment-free complete remission
Ramy czasowe: Three Months, six months and twelve months after inebilizumab treatment
|
Flare-free and treatment-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Proportion of subjects achieving flare-free and glucocorticoid-free complete remission
Ramy czasowe: Three Months, six months and twelve months after inebilizumab treatment
|
Flare-free and glucocorticoid-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Remission rate after inebilizumab treatment
Ramy czasowe: Six months and twelve months after inebilizumab treatment
|
The investigator determined that there was no evidence of disease activity at the visit |
Six months and twelve months after inebilizumab treatment
|
|
IgG4-RD Responder Index (IgG4-RD RI) after inebilizumab treatment
Ramy czasowe: Three Months, six months and twelve months after inebilizumab treatment
|
Measured by IgG4-RD Responder Index |
Three Months, six months and twelve months after inebilizumab treatment
|
|
IgG4-RD Damage Index (IgG4-RD DI) after inebilizumab treatment
Ramy czasowe: Three Months, six months and twelve months after inebilizumab treatment
|
Measured by IgG4-RD Damage Index |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Changes in serum IgG4 levels from baseline after inebilizumab treatment
Ramy czasowe: Three Months, six months and twelve months after inebilizumab treatment
|
Laboratory markers |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Changes in serum B-cell levels from baseline after inebilizumab treatment
Ramy czasowe: Three Months, six months and twelve months after inebilizumab treatment
|
Laboratory markers |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Total amount of glucocorticoids during inebilizumab administration
Ramy czasowe: One year after inebilizumab treatment
|
Total amount of glucocorticoids calculated as the cumulative glucocorticoid dose (in milligrams) taken for the purpose of IgG4-RD disease control. This measure accounted for all glucocorticoids treatments administered to participants to manage disease activity throughout the study period. |
One year after inebilizumab treatment
|
|
Improvement in patients' quality of life during inebilizumab administration
Ramy czasowe: One year after inebilizumab treatment
|
Quality of life measured by the EQ-5D-5L questionnaire |
One year after inebilizumab treatment
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- I-26PJ0909
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
IPD will not be shared with other researchers. Data may be made available to regulatory authorities, trial monitors, auditors, and ethics committees as required for trial oversight, monitoring, audit, and verification.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .